相关临床试验
13
9 进行中
药物批准
53
批准总数
监管机构
6
监管机构数
成立时间
1990
进行中（未招募）
9
69.2%
已完成
2
15.4%
招募中
2
15.4%
- Recordati Rare Diseases presented updated real-world safety data from the CADENCE registry showing no new safety signals for ENJAYMO (sutimlimab) after an average treatment duration of more than two years in 63 patients with cold agglutinin disease. - The analysis revealed that 52.4% of patients experienced adverse events, with only 9.5% considered related to sutimlimab treatment, and one unexpected serious adverse event of chest pain/stable angina. - The safety findings from this multinational prospective registry were consistent with earlier clinical trial data, supporting the continued use of sutimlimab for treating hemolysis in adults with cold agglutinin disease. - CADENCE represents the world's largest dataset for treatment patterns in cold agglutinin disease and cold agglutinin syndrome, providing valuable real-world evidence for this rare autoimmune condition.
- Recordati Rare Diseases presented four studies at ASH 2025 showcasing advances in Castleman disease understanding, including the first AI-based histopathology grading model for automated diagnosis. - The BURDEN-iMCD study revealed that patients with idiopathic multicentric Castleman disease have 6.9-fold higher morbidity rates and 7.61-fold higher healthcare costs compared to matched controls. - Pediatric analysis from the ACCELERATE registry showed children with iMCD experience more severe disease than adults but respond similarly to siltuximab treatment. - A 20-year cohort study of 217 patients provided new insights into Castleman disease subtypes, confirming TAFRO as the most aggressive form with the poorest survival outcomes.
- Recordati Rare Diseases will present nine poster presentations at the 67th American Society of Hematology Annual Meeting, showcasing advances in Castleman disease, cold agglutinin disease, and CAR T-cell therapy complications. - Key highlights include the first real-world evaluation of sutimlimab for cold agglutinin disease and an innovative AI model for Castleman disease tissue analysis to improve diagnosis. - The research portfolio demonstrates Recordati's commitment to addressing rare hematologic disorders, with studies covering both pediatric and adult populations across multiple therapeutic areas.
